Latest Capital Raising News

Story-i Limited has agreed to acquire LIT Energy Network Australia for AUD 8 million, targeting Vietnam’s booming electric motorcycle market. The deal comes as Story-i prepares for ASX delisting and a $5 million capital raise.

Sandon Capital Investments has announced a modest increase in its annual dividend and will begin paying fully franked dividends monthly, aiming to provide shareholders with more frequent income amid a changing economic backdrop.

Aurelia Metals Limited has reported a strong turnaround with a $48.9 million net profit for FY25, driven by operational progress at its Federation Mine and the approval of the Great Cobar Project. The company’s strategic focus on base metals growth and sustainability underpins its improved financial and safety performance.

Felix Group Holdings Ltd has launched a capped $1 million Share Purchase Plan (SPP) offering eligible shareholders a discounted entry to support its strategic acquisition of Nexvia Pty Ltd and fuel growth initiatives. This retail-focused SPP complements a larger institutional placement as Felix aims to expand its enterprise software footprint.

Felix Group Holdings has launched a $1 million Share Purchase Plan offering shares at a 3.7% discount to support its acquisition of Nexvia Pty Ltd and growth initiatives.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Energy Transition Minerals Ltd has successfully raised $8 million through a heavily oversubscribed Share Purchase Plan, closing early due to strong shareholder demand. The funds will support the company’s critical minerals development strategy in Europe.

Activeport Group has successfully closed a fully underwritten rights issue, raising approximately $2.5 million to support its telecommunications software ambitions. The offer included free attaching options, signaling confidence in future growth.

Actinogen Medical reports steady progress in its Alzheimer’s and depression drug trials, backed by strong funding and strategic commercial planning. Key interim data from the pivotal XanaMIA trial is expected early next year.

Actinogen Medical reported a $14.7 million net loss for FY25 while progressing its lead drug Xanamem through pivotal Alzheimer’s and depression trials, with interim results expected in January 2026. The company has secured funding through mid-2026 and is preparing for commercialization.

Felix Group Holdings Ltd has announced a $1 million share purchase plan, offering eligible shareholders the chance to buy shares at $0.21 each starting 26 August 2025.

The Australian Wealth Advisors Group Ltd (AWAG) reported a $1.18 million net profit before tax in its first full year as an ASX-listed company, reversing a prior loss and growing revenue by 13%. The company expanded its funds under management and equity investments, positioning itself for further industry consolidation.